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The development and application of methods to prevent the transmission of damaging mutations through the human germ line would have considerable health benefits. In an attempt to correct a paternal pathogenic mutation using CRISPR-Cas9 technology in human embryos, Ma et al. 1 assert that the maternal allele is an efficient repair template for gene correction, including when Cas9 is applied in metaphase II (MII) oocytes. As the maternal and paternal genomes undergo distinct developmental programs and are in separate nuclei before the first mitotic division, which would seem to preclude inter-homologue interactions, we believe that it is crucial to provide a comprehensive analysis of the molecular outcomes of double-strand break (DSB) repair in human embryos. In the absence of direct molecular evidence for the inferred events, the consideration of using such methods for correction of the human germ line should proceed with extreme caution. There is a Reply to this Comment by Ma, H. et al. Nature 560, https://doi. org/10.1038/s41586-018-0381-y (2018).
Ma et al. 1 use two approaches to attempt gene correction in human embryos. In one approach, which is deemed to be more promising because it is thought to give rise to non-mosaic embryos, MII oocytes were injected with donor sperm from a heterozygous mutation carrier together with Cas9 complexes to direct the cleavage of the mutant paternal allele. About 72% of embryos arising from Cas9 injection were thought to be wild type compared with 50% of control embryos. The authors argue that this excess of apparently wild-type embryos (22%) arose by correction of the paternal allele, by using the maternal allele as a repair template, a process termed inter-homologue homologous recombination (abbreviated here as IH-HR).
In the other approach, Ma et al. 1 again used sperm from the mutation carrier to fertilize wild-type oocytes; when the pronuclear-stage zygotes were completing S phase, they were injected with Cas9 complexes, again directed to the mutant paternal allele. In contrast to the previous approach, embryos derived from fertilization with mutant sperm could be conclusively identified because mosaic embryos were obtained. Some cells of these mosaic embryos contained a mutant paternal locus, either unmodified or with small indels, together with the wild-type maternal allele. Other cells in these mosaic embryos contained only a detectable wild-type allele. The authors inferred that these cells arose by IH-HR of the mutant paternal allele using the wild-type maternal allele as a template, leading to gene correction.
Considering the data presented in Ma et al. 1 , alternatives to IH-HR are possible. Genotyping involved the amplification of an approximately 534-base-pair (bp) fragment in which the MYBPC3 ΔGAGT mutation is approximately 200 bp from one of the primer-binding sites. Deletions larger than 200 bp would be sufficient to remove this primer-binding site and lead to amplification of only the maternal allele (Fig. 1a, b) , giving the misleading appearance of gene correction of the paternal allele. Although typically not as common as small indels, long deletions and other events have been detected in cultured cells and in both mouse and pig zygotes [2] [3] [4] . To detect longer deletions, a matrix of primer pairs needs to be tiled at increasing distances from both sides of the mutation; linkage analysis performed on the long-range PCR products would confirm whether amplification is from both the maternal and the paternal chromosomes. In a study designed to score these events systematically, Cas9-induced double-strand breaks in mouse embryonic stem cells were found to resolve into large deletions (250-9,500 bp) in approximately 20% of edited cells 5 . This approach remains imperfect to detect all events, however, because very large deletions or other events such as inversions, translocations, chromosome loss and large insertions prevent amplification and thus will escape characterization. Indeed, in 19% of cells edited at an autosomal locus, only one of two alleles could be recovered 5 . These various outcomes of repair of a DSB could result in genotypes incompatible with normal development, and therefore need to be reliably identified to exclude affected embryos.
Wild-type genotypes in a PCR assay can also arise by the activation of the egg during Cas9 injection, but without successful integration of a sperm genome, resulting in haploid or diploid parthenogenetic cells containing only the maternal genome 6 (Fig. 1c) . A paternal contribution was verified by cytogenetic analysis in some of the stem-cell lines generated from embryos by Ma et al. 1 , but the authors did not determine whether wild-type stem-cell lines were from wild-type sperm, or arose by gene correction.
To directly demonstrate gene correction by IH-HR, evidence for a new linkage of maternal and paternal alleles-that is, through the incorporation of the wild-type sequence from one of the maternal homologues into the mutant paternal chromosome at the site of the DSB-is required (Fig. 1a) . New DNA linkages can be determined by phased DNA sequencing, or by long-range PCR using allele-specific primers 7, 8 . Such haplotype analysis is particularly crucial in the case of the embryos derived from MII-phase oocyte injections, because which embryos were derived from sperm carrying the mutant allele was not determined.
Although IH-HR in fertilized oocytes and zygotes cannot be excluded, there are several obstacles to this mechanism. IH-HR after the induction of a DSB in mitotic mammalian cells has been described 11 , and was also seen in a recent study using CRISPR-Cas9 in embryonic stem cells 5 , though it was less frequent than inter-sister HR or NHEJ. In mammals, IH-HR is essential for the reductional division to form gametes, and is promoted by the large number of DSBs that are programmed to form on each chromosome 9 . It is important to note, however, that meiotic IH-HR occurs during fetal development in females 10 and so it is temporally removed from the events described in Ma et al 1 .
The physical separation of maternal and paternal genomes in fertilized eggs would be expected to be a substantial impediment to IH-HR during the first cell cycle. After fertilization, distinct maternal and paternal nuclei form (pronuclei), such that the two genomes are separate in a cell that is more than 100 µm in diameter (Fig. 1d-g ). This separation may prevent the incorporation of paternal chromosomes into the oocyte MII spindle (Fig. 1e) . During the first interphase, maternal and paternal pronuclei migrate from the site of their formation towards the centre of the zygote, but their integrity persists throughout interphase (Fig. 1f, g ), during which individual nuclei can be manipulated 12 . In both human and mouse zygotes, maternal and paternal genomes undergo DNA replication in separate nuclei, and enter the first mitosis as separate entities, at which time they can still be individually manipulated (Fig. 1f, g ). Microtubule action assembles maternal and paternal genomes on a common metaphase plate at the Brief CommuniCations arising first mitosis 13, 14 , although they remain in distinct groups 15 . Therefore, direct contact between maternal and paternal genomes required for inter-homologue repair does not seemingly occur until the first mitosis or later when embryos enter the two-cell stage and the two genomes are packaged within the same nucleus. Relative to the application of Cas9, this is 24-30 h after the MII injections, and 6-12 h after the zygotic injections.
It is important to note the different outcomes Ma et al. 1 obtained with regards to mosaicism depending on whether CRISPR-Cas9 was injected into zygotes (frequent mosaicism) or together with sperm into MII-phase eggs (lack of apparent mosaicism). Mosaicism from zygotic injection is consistent with DSB repair occurring after DNA replication, whereas the lack of mosaicism after MII-phase injection indicates that repair occurs before DNA replication and thus before the first mitosis. Consistent with this, the injection of CRISPR-Cas9 together with sperm in mouse MII oocytes results in non-mosaic modification of the paternal genome within only 3 h owing to NHEJ during sperm ∆GAGT locus. Red and blue circles indicate unique maternal and paternal genetic variants, respectively. IH-HR results in gene conversion of the paternal allele by the wild-type (WT) maternal allele. The repair outcome can be a non-crossover or a crossover. Only one outcome of crossing-over is shown, in which the recombined chromosomes segregate to the same nucleus. The alternative is that the recombined chromosomes segregate to different daughter cells, such that loss of heterozygosity would occur on the chromosome from the point of the IH-HR event to the telomere in both daughter cells, one with homozygosity for the maternal chromosome and the other for the paternal chromosome. This outcome would be expected in half of the crossing-over events that underwent IH-HR in the G2 phase of the cell cycle. NHEJ can lead to small indels (not shown), but events are also possible that result in the deletion of a primer-binding site used for genotyping (as shown). b, Schematic of possible repair outcomes after Cas9 cleavage in the human zygote from panel a. m, maternal chromosome; p, paternal chromosome. c, Parthenogenesis after fertilization failure with (top) and without (bottom) second polar body (PB) extrusion. Outcomes of a-c are indistinguishable in genotyping assays using flanking PCR primers alone. d, Schematic of intracytoplasmic sperm injection (ICSI) followed by progression through the first cell cycle during day 1 of development. The number of maternal and paternal genomes is indicated at each phase of the cell cycle. e, Immunofluorescence of a mouse zygote at telophase of the second maternal meiotic division. Note that only the maternal genomes are attached to microtubules, while the paternal genome begins to form an interphase nuclear membrane to replace the sperm membrane. BF, bright field. f, Progression of human zygotes through the first cell cycle from the two-pronuclear stage to prometaphase, when the two genomes can be removed from the egg by a needle. Note the separation of the two genomes (arrows and dashed circles). NEBD, pronuclear envelope breakdown. g, Cell cycle progression during day 1 in fertilized mouse zygotes. Of 23 mouse eggs, none showed direct contact between the maternal and paternal genomes. Scale bars, 10 µm. Images one and four (from the left) in f are from Egli et al. 14 ; images four to six (from the left, top) in g are from Egli et al. 13 .
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Inter-homologue HR (crossover Brief CommuniCations arising chromatin decondensation 16 . Notably, the maternal genome seems to be refractory to editing during this time of meiotic exit. Different outcomes depending on the time of CRISPR-Cas9 injection indicate that gene editing in the paternal genome during decondensation or after the formation of a nucleus may involve different repair mechanisms.
In summary, the direct verification of gene correction and exclusion of other possible outcomes is an imperative for any embryo that would be considered for future implantation. Gene editing has the potential to reduce disease-causing alleles, but inadvertent changes to the human germ line, including rearrangements, long deletions, and loss of heterozygosity, for example, from IH-HR, could have serious consequences that affect development, predisposition to cancer and fertility. Our discussion of Ma et al. 1 demonstrates the need for a more comprehensive characterization of the repair mechanisms in the early embryo, and identifies a key challenge for the therapeutic use of gene editing in the human germ line: the development of reliable assays to distinguish between different repair outcomes when DNA is limiting.
Methods
Mouse oocytes were obtained from 5-7-week-old B6D2F1/J females (Jackson Laboratories stock 10006) by superovulation. Oocytes were removed from oviducts 14 h after injection of human chorionic gonadotropin, and fertilized with mouse sperm injection by ICSI on an inverted Olympus IX73 equipped with a Narishige micromanipulator. Images were taken using an Olympus IX73 equipped with an Olympus DP80 camera (Fig. 1f) or a Zeiss 710 confocal microscope at indicated time points (Fig. 1e) . Immunostaining was performed using a monoclononal beta tubulin antibody (clone AA2, Millipore 05-661, dilution 1:1,000, lot 2370698) in PBS with 10% FBS for 3 h at room temperature. Secondary antibody Invitrogen 488 donkey anti mouse (A21202) at 1:500 dilution in PBS for 45 min at room temperature. Hoechst 33342 was used for DNA staining at 5 µg ml In a recent publication, Ma et al. 1 reported the correction of a heterozygous paternally inherited MYBPC3 mutation in human zygotes using CRISPR-Cas9 genome editing. We read their work with interest, especially the interpretation that the wild-type maternal allele was used as template to repair the DNA break at the mutation site. We think there are other explanations, specifically that repair of CRISPRCas9 single cleavage at the mutation site generates large deletions that prevent PCR amplification of the paternal chromosome, thereby giving the appearance of inter-homologous repair. Ma et al. 1 did not perform experiments to exclude this possibility, and we therefore sought to test this idea in mouse embryos, which closely model the development of human zygotes. There is a Reply to this Comment by Ma, H. et al. Nature 560, https://doi.org/10.1038/s41586-018-0381-y (2018).
Similar to Ma et al.
1
, we delivered the CRISPR reagents into zygotes using microinjection. We used Cas9 mRNA as opposed to CAS9 protein, as this approach has been shown to generate on-target mutations with high efficiency 2 . Guide RNAs (gRNAs) were identified for six autosomal loci. Three of the gRNAs targeted coding regions of genes that do not cause nullizygous lethality (Rsad2 (also known as viperin), Pik3r6 and Hmgcs2) and three targeted intronic or flanking regions (Neurog3 (also known as Ngn3), Foxp4 and Fzd3). Altogether, 127 founder embryos/mice were generated from zygotes microinjected with each gRNA. To assess the mutation efficiency at each locus, we used the polyacrylamide gel heteroduplex mobility assay (HMA) 3 to screen 300-600 base-pair (bp) PCR products that span the gRNA target sites. The HMA detected mutations in 76 out of 127 (60%) of samples (Supplementary Information tab 1). These included 13 samples that generated considerably smaller PCR products than expected, indicating that they contain large deletions in the order of 100-300 bp (Supplementary Information tab 1) . Notably, four samples failed to amplify, suggesting bialleic deletion of PCR primer-binding sites (Supplementary Information tab 1) . To confirm the results of the HMA, we performed Sanger sequencing of the PCR products. As expected, mutations were detected in all HMA-positive samples (Supplementary Information tab 2). Notably, 93% of the HMA-negative samples that we sequenced contained a small indel compared with the wild-type sequence (Supplementary Information tab 3 ). Only one type of mutation was observed in most of these samples, which explained why they were not detected by HMA (false negatives). Taken together, these data show that mutations were generated in 98% of CRISPR-Cas9-microinjected zygotes.
Next, we screened specifically for large deletions using an approximately 1.6-kb PCR with primers that were equidistant from gRNA PAM sequences. Notably, we generated amplicons that were considerably less than 1.6 kb (indicating large deletions) in 35 samples. These low molecular mass products were not generated in the initial 300-600-bp PCR, indicating that they corresponded to deletions that encompass at least one of the (initial) PCR primer-binding sequences. Large deletion products were also identified in 9 additional samples when we performed an approximately 3.2-kb PCR on the Neurog3 and Foxp4 founders (Supplementary Information tab 4) . These larger PCRs also generated amplicons from samples that failed to amplify in the initial 300-600-bp PCR, confirming that these contained large deletion alleles. Altogether, the number of samples containing detectable large deletions (more than 100 bp) was 57 out of 127 (45%; Fig. 1a , Supplementary  Information tab 4) , noting that some founders were mosaic and some contained more than one large deletion event. Large deletions were detected in 57% of the HMA-negative samples, indicating that these large deletions contributed to the amplification failure in the HMA false-negative samples. The remaining mutant HMA-negative samples may contain larger deletions that require further separation of PCR primers for detection, or may be homozygous for the indel mutation. Deleted sequences were confirmed by direct sequencing of gelpurified PCR products (Supplementary Information tab 5). Each gRNA generated a range of unique deletions, indicating that the process that underpins the generation of large deletions is stochastic (Fig. 1b,  Supplementary Information tab 5) . Notably, we observed that the orientation of the large deletions was asymmetric or unidirectional with respect to the cutting site (Fig. 1b, Supplementary Information tab 5 ). The size of the large deletions (after 1.6-kb PCR) ranged from 100 to 800 bp (Fig. 1b) , with the largest deletion of 2.3 kb detected in a Foxp4 sample after 3.2-kb PCR (Supplementary Information tabs 4 and 5, sample Foxp4 #19).
Because the detection of large deletions using PCR is prone to amplification bias and is confounded by the deletion of primer sequences, we next sought to use an unbiased approach using PCR-free pairedend whole-genome sequencing (WGS) to determine the frequency and extent of large deletions in CRISPR-Cas9-treated mouse embryonic stem (ES) cells. We transfected ES cells with plasmid PX459.V2.0 4 that expresses Cas9 and Rsad2 gRNA, and puromycin-resistant transfectants were obtained for genomic DNA (gDNA) extraction and WGS analysis. Of 88 sequence reads that span the Rsad2 single gRNA cleavage site, only two (2.3%) corresponded to wild-type alleles. Small indels and substitutions were found in 33 reads (37.5%), and large deletions inferred from discordant mapping of paired-end reads and split read mapping over the breakpoint were detected in 33 reads (37.5%) (Fig. 1c) . The remaining 20 reads (23%) unexpectedly contained insertions of the PX459.V2.0 expression plasmid. Together, these data confirm that large deletions are frequently generated after CRISPRCas9-mediated DNA cleavage in mouse ES cells and zygotes.
In summary, our data demonstrate that large deletions are frequently generated in mouse zygotes after CRISPR-Cas9 single cleavage, as has recently been noted by others [5] [6] [7] . Although species differences may affect DNA repair products, Ma et al. 1 cannot conclude with certainty that the purported homology-directed repair gene correction event has generated homozygous wild-type embryos until the existence of large deletions is excluded. This could be investigated by generating larger PCR products as described above. Quantitative PCR analysis to confirm the presence of both wild-type alleles would provide definitive evidence. The importance of accurate genotyping in the context of human germ-line modification cannot be overstated. Failure to detect large deletions could lead to disastrous outcomes in potential clinical applications.
Methods
gRNAs were designed using the online CRISPR tool developed by the Zhang laboratory at MIT (http://crispr.mit.edu) 8 . Cas9 mRNA (100 ng µl −1 ) and gRNAs (50 ng µl −1 each) were injected into the cytoplasm of C57BL/6N zygotes using a FemtoJet microinjector, transferred to pseudo-pregnant recipients, and allowed to develop to term or collected as embryos. gRNA sequences were as follows: Neurog3 5′-GCACAGCTGGATTCCGGACAAA-3′; Foxp4 5′-CCAGCGTTCCCATTGTCCTT-3′; Fzd3 5′-CTTAGCAAGG 
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A description of all covariates tested The two accompanying Comments 1,2 highlight the results of our recent study 3 and their implications for understanding the basic biology of DNA repair and for potential future therapies. Given the importance of the conclusions of our study 3 , further verification was requested to rule out alternative interpretations. One argument made by Egli et al. 2 was that the repair of the mutant paternal allele using maternalhomologous sequences is highly unlikely based on the assumption that in early zygotes, parental genomes are physically separated in paternal and maternal pronuclei. This temporary isolation would therefore preclude homologous chromosome interactions required for homologydirected repair (HDR). However, it should be noted that CRISPRCas9 ribonucleoprotein (RNP) specific to the mutant paternal allele was delivered into pronuclear-stage zygotes or even earlier during fertilization in our original study 3 , while the subsequent readouts of targeting and repair outcomes were measured three days later in multicellular embryos 3 . In late mammalian zygotes, paternal and maternal pronuclei migrate towards each other with subsequent nuclear envelope breakdown and formation of a diploid mitotic spindle 4, 5 . Thus, from this point onwards, parental homologues are presented with ample opportunities to physically interact and recombine. Although we do not exclude the possibility of initial targeting and induction of double-strand breaks (DSBs) in metaphase II (MII) oocytes or zygotes at the time of CRISPR-Cas9 injections, HDR or non-homologous end-joining (NHEJ) could have occurred later during subsequent three mitotic cell cycles. Indeed, we showed that each mosaic 4-8-cell embryo contained blastomeres with two or more different repair outcomes suggesting that CRISPR-Cas9 remains active well beyond the pronuclear stage.
On the basis of the assumption that HDR in pronuclear stage zygotes is impossible, Egli et al. 2 and Adikusuma et al. 1 suggested that our results could also represent 'loss' in the detection of the mutant paternal allele altogether owing to large deletions. Such genetic lesions could prevent PCR primer binding and amplification, thus subsequently escaping detection. Adikusuma et al. 1 indicated the possibility of CRISPR-Cas9 inducing large deletions (greater than 100 base pairs (bp)) at the targeted region, particularly, when disrupting both parental alleles simultaneously. Previous mouse studies showed that the most frequent deletions induced by a single single-guide RNA (sgRNA) do not exceed 10 bp and occurrence of larger deletions are rare to account for the high rates of HDR (above 50%) observed in our experiments 6 .
We designed and pre-tested different sgRNAs in patient induced pluripotent stem cells (iPSCs) and selected one with high specificity for the mutant sequence with no evidence of large deletions detected, making it unlikely, in our view, that our selected sgRNA would induce a large deletion at the frequency we observed for HDR. A recent report also demonstrated that pre-testing of several candidate sgRNAs in human embryonic stem (ES) cells could be effective in predicting editing efficacy of disrupting both copies of POU5F1 in human embryos 7 . In this study, the most frequently observed on-target editing in CRISPR-Cas9-microinjected human embryos were small (2-3 bp) indels. Only one embryo contained a few blastomeres with uncommonly large 330-bp deletions 7 . Although species differences may have impacted editing outcomes, Adikusuma et al. 1 did not report pre-testing candidate sgRNAs.
Moreover, we used CRISPR-Cas9 RNP, whereas Adikusuma et al. 1 used Cas9 mRNA, which may have accounted for large deletions.
Nevertheless, to rule out the possibility of large deletions, we decided to carry out a large-scale re-testing of all embryonic blastomere samples from our published study. Originally, we used PCR amplification followed by Sanger sequencing of a 534-bp fragment spanning approximately 250 bp in each direction from the MYBPC3 ΔGAGT mutation site. To detect larger deletions, we designed an additional 8 pairs of long-range PCR primers amplifying various lengths of fragments surrounding the MYBPC3 ΔGAGT mutation locus ranging from 493 bp to 10,160 bp (PCR1-PCR8 in Fig. 1a ; Extended Data Table 1 ). First, we re-tested 8 blastomeres with wild-type maternal and paternal genotypes (WT/WT) from the 4 mosaic embryos S-phase-injected with CRISPR-Cas9 (Extended Data Table 2), along with 4 WT/WT and 4 wild-type maternal and mutant paternal (WT/Mut) blastomeres from the non-injected control embryos (Extended Data Table 3 ). PCR products were separated on 1% agarose gels. In all 16 samples, primers PCR1, PCR2, PCR4 and PCR5 amplified a single band of the expected size (Fig. 1b-e) . For PCR6 and PCR7, several faint bands of smaller size were also detectable in some corrected and control blastomeres (Fig. 1f,  g ). However, Sanger sequencing of these faint bands did not produce any readable products suggesting non-specific PCR primer binding. Next, we performed 2 additional long-range PCR amplifications with PCR3 and PCR8 primers on all remaining WT/WT blastomeres (n = 35) from the 13 mosaic embryos along with controls (Extended Data Table 2 and 3) . Amplification with PCR3 produced a single band of the expected 1,742 bp size in all experimental and control blastomeres (Fig. 1h) . For PCR8, in addition to a major band matching the expected 10,160 bp size, a few faint smaller size bands were also visible in some targeted and control samples, but again, Sanger sequencing indicated non-specific primer binding (Fig. 1i) .
We next screened for larger deletions in the M-phase-injected embryos and randomly selected one blastomere from every WT/WT embryo (n = 41) as all individual blastomeres within each embryo in this group carried identical MYBPC3 genotypes. We also tested the only mosaic embryo (M2-WT42) in this group that contained 3 blastomeres with WT/WT genotypes and 4 blastomeres with WT/ssODN (Extended Data Table 4 ). Again, long-range PCR screening of all samples with primers PCR3 and PCR8 produced a single band of expected 1,742 bp or 10,160 bp size, that is, failing to detect large deletions (Fig. 1j, k) .
We also examined whole-exome sequencing (WES) results for large deletion in the 6 human ES cell lines derived from M-phase-injected embryos. Comparisons of the area 5 kb downstream and 5 kb upstream from the mutation site in ES cells and the corresponding egg and sperm donors revealed no differences in sequencing depth, consistent with the absence of any large deletions (Extended Data Fig. 1) .
We then designed two additional 16-kb and 20-kb PCR primers in an attempt to screen for even larger deletions; however, these primers failed to produce a detectable response. All DNA samples were extracted from single blastomeres and then pre-amplified by whole-genome amplification. It is likely that whole-genome amplification results in smaller size DNA segments not compatible for amplification with 16-kb and 20-kb PCR. 
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In summary, all these tests failed to detect the presence of large deletions up to ±5 kb from the mutation site in CRISPR-Cas9-treated human embryos. Although the PCR primers used in this study did not identify much larger deletions, available evidence suggests that most deletions induced by CRISPR-Cas9 should have been detected with our assays. The use of multiple sgRNAs targeting several sites may produce large deletions of up to 24-kb DNA segments; however, the use of single sgRNA has resulted in smaller deletions of less than 600-bp DNA in mouse embryos 6 .
Our original results suggest that DSB repair on the paternal allele governed by maternal homologue-based HDR extends to the adjacent ΔGAGT deletion site resulting in conversion of the paternal sequence (see extended data figure 2a of the original study 3 ). Therefore, we asked whether DNA proofreading and mismatch repair mechanisms involved in HDR could also contribute to the conversion of neighbouring neutral paternal SNPs resulting in loss-of-heterozygosity (LOH) within the MYBPC3 locus. We postulated that paternal single nucleotide polymorphisms (SNPs) adjacent to the targeted DSB locus would be 
converted to become maternal-like, while more distant polymorphic sites would be preserved. We searched WES and whole-genome sequencing (WGS) datasets and identified three informative parental SNPs within the MYBPC3 gene distinguishing egg donor 1 from the sperm donor. SNPs #1 (rs2071304) and #2 (rs2856650) were located downstream of the ΔGAGT deletion site (−7,959 bp and −781 bp), whereas SNP #3 (rs2856653) was +3,335 bp upstream from this locus (Fig. 2a) . We next genotyped individual blastomeres of the two CRISPR-Cas9-injected mosaic embryos (Mos2 and Mos3 in Table 1 ) from this parental combination. The ES cell line (ES-C1) derived from the control non-injected, blastocyst from the same parental combination was also genotyped. ES-C1 with the WT/WT genotype at the mutation locus and two blastomeres, Mos2.3 and Mos3.2, from the mosaic embryos with the WT/NHEJ genotype were heterozygous at all three polymorphic sites representing the expected maternal and paternal SNPs (G/C, T/C and G/A for SNPs #1, #2 and #3, respectively) ( Table 1 and Fig. 2b ). By contrast, the two blastomeres Mos2.1 and Mos3.1 with the WT/HDR genotypes from the same mosaic embryos were homozygous for all three SNP sites carrying exclusively maternal nucleotides. Notably, another blastomere, Mos2.2, also with a WT/HDR genotype, was homozygous at the SNP #2 locus carrying maternal nucleotides, but heterozygous at both SNP #1 (G/C) and SNP #3 (G/A), indicating preservation of these paternal SNP sites (Table 1 and Fig. 2b) . These results support the notion that HDR-based conversion can expand beyond the targeted mutant loci, resulting in loss of neutral paternal SNPs across the MYBPC3 region. However, the acquisition of maternal SNPs by something other than long conversion tract cannot be completely ruled out. In contrast to the mosaic counterparts, the MYBPC3 genotype of the original sperm in uniform WT/WT embryos produced from CRISPRCas9-treated zygotes or oocytes cannot be determined. Nevertheless, we suggested that some embryos with MYBPC3
WT/WT genotypes could have originated from mutant MYBPC3
ΔGAGT sperm, with subsequent HDR correction of the deletion. This original assumption was based on a significant increase in the percentage of WT/WT embryos in the CRISPR-Cas9-treated group compared to non-treated controls 3 . We reasoned that loss of neutral paternal SNPs in some of these WT/WT embryos could be used as evidence of repair of the mutant MYBPC3 ΔGAGT . Among 42 WT/WT, M-phase-injected embryos, six (M2-WT28 to M2-WT33 in Table 1 ) were derived from the egg donor 1 and the sperm donor, and thus should be heterozygous at the SNP #1, #2 and #3 sites. We randomly genotyped two sister blastomeres from each of these six embryos, and documented LOH in at least one of these polymorphic sites in four embryos. As expected, paternal SNPs were lost at these loci, resulting in homozygous maternal nucleotides (Table 1 and Fig. 3) . Notably, genotypes of two sister blastomeres from the same embryo were distinct from each other, suggesting independent HDR events probably occurred at the two-cell stage or later. For example, one blastomere (M2-WT29.3) in embryo M2-WT29 was homozygous at all three SNP loci carrying exclusively maternal nucleotides while the other sister blastomere (M2-WT29.2) was heterozygous at all three SNP sites (Table 1 and Fig. 3) . A similar pattern was also observed in embryos M2-WT 30 and 32. By contrast, one blastomere (M2-WT31.1) of embryo M2-WT31 was homozygous containing maternal alleles at the SNP #2 and #3 (T/T and G/G, respectively), whereas the more distant SNP#1was heterozygous (G/C). Its sister blastomere M2-WT31.2 was heterozygous at these three SNP positions.
As indicated above, LOH associated with erasure of paternal SNPs in these four uniform WT/WT embryos provides support for repair of the mutant sperm MYBPC3
ΔGAGT deletion following CRISPR-Cas9 treatment. Additional genotyping of distant SNPs throughout chromosome 11 from all parental contributions would be necessary to establish the median conversion tract length. All examined blastomeres in the remaining embryos, M2-WT28 and M2-WT33, were heterozygous at all three SNP sites, suggesting that these embryos were fertilized by wild-type sperm.
We extended SNP analysis to four uniform WT/WT embryos from the S-phase-injected group from the same parental combination. Three embryos (WT4, WT5 and WT6) were heterozygous for all three SNPs, whereas both blastomeres examined from WT3 embryo were heterozygous at SNP #1 and #3 but homozygous at SNP #2 (Table 1 and Fig. 3) . Thus, this embryo was probably generated from the mutant sperm but subsequently corrected by HDR using the wild-type maternal allele.
To provide further genetic evidence for HDR, we also screened egg donor 2 and identified two informative SNPs within the MYBPC3 gene that would differentiate from the paternal contribution. Egg donor 2 was homozygous (G/G) at the SNP #4 site (positioned −6,189 bp downstream of the ΔGAGT mutation, rs2697920), whereas the sperm At SNP #5 (+9,514 bp, rs11570115), both parents were heterozygous A/G. We initially genotyped blastomeres with WT/NHEJ or WT/Mut genotypes from seven mosaic embryos (Mos1, Mos7, Mos8, Mos10, Mos11, Mos12, and Mos13) derived from this parental combination, and found that six were heterozygous A/G at the SNP #4 locus ( Table 2 , footnote symbol b), indicating that mutant sperm contributed the ' A' allele at this locus in these embryos. We next sequenced all sister blastomeres with WT/HDR genotypes from these six embryos and found that five (Mos1, Mos7, Mos8, Mos10 and Mos13) contained one or more blastomeres that lost the paternal allele and became homozygous G/G at SNP #4, supporting the gene conversion from maternal allele ( Table 2 and Extended Data Fig. 2b ). The remaining WT/HDR blastomeres in these embryos retained the paternal allele and were heterozygous A/G at the SNP#4, probably indicating a shorter conversion tract. Both WT/HDR blastomeres from Mos11 embryo were heterozygous A/G at SNP #4. WT/Mut blastomere from Mos12 embryo was homozygous G/G at SNP #4, precluding the need for further genotyping determinations (Table 2) . We next sequenced one randomly selected blastomere from each of the seven uniform WT/WT, M-phase-injected embryos generated from the egg donor 2 and the sperm donor. We found all seven blastomeres were homozygous G/G at SNP #4 (Table 2 ). In comparison, six out of seven S-phase-injected mosaic embryos generated from the same parental combination were heterozygous A/G (Table 2) . Therefore, we think it is possible that some of these G/G homozygous embryos in the M-phase-injected group also lost paternal SNPs owing to gene conversion. Genotyping for the SNP #5 locus showed that two mosaic S-phase-injected embryos (Mos1 and Mos8) were heterozygous A/G and informative for conversion analyses ( Table 2 ). All five sister blastomeres with WT/HDR genotypes in the Mos1 embryo were homozygous G/G at SNP #5, indicating loss of paternal SNPs. Of the two WT/HDR blastomeres in Mos8 embryo, one was homozygous G/G and one was heterozygous A/G at SNP #5. Among M-phase-injected embryos, one out of seven was heterozygous A/G and the remaining six were homozygous G/G at SNP #5 (Table 2) .
Together, these results suggest that gene conversion in human embryos induced by HDR may happen and extend considerable distances in both directions from the original target site, resulting in LOH associated with erasure of neutral paternal SNPs. The length of the conversion tract varied among individual blastomeres even from the same embryo. The existence of polymorphic sites and retention of paternal SNPs on some corrected blastomeres also provides a strong suggestion that the mutant paternal MYPBC3 locus was repaired in embryos injected at the S phase and M phase.
In our original study 3 , we demonstrated that early exposure to CRISPR-Cas9 RNP during fertilization (M phase) could considerably reduce or completely eliminate mosaicism in cleaving embryos. 
These results are irrespective of whether repair occurred via HDR or NHEJ because mosaic embryos may include blastomeres with different NHEJ-derived indel genotypes. Egli et al. 2 dispute our interpretation and speculate that the decrease in mosaicism in our M-phase-injected group could be due to fertilization failure resulting in parthenogenetic development of oocytes. We showed that only 1 out of 58 (1.7%) cleaving embryos produced by M-phase-injection was mosaic, and 16 out of 58 (27.6%) were uniformly heterozygous, carrying NHEJ-derived indels in the mutant paternal allele (MYBPC3
WT/∆GAGT-indel
; figure 3b of the original study 3 ). These heterozygous embryos could not originate from parthenogenesis because they all carry the paternal MYBPC3 deletion. By contrast, when CRISPR-Cas9 was injected one day after fertilization into late S-phase zygotes, 13 out of 54 (24%) embryos were mosaics (figure 2a of the original study 3 ). Egli et al. 2 argue that the increased yield of WT/WT embryos (22%) in the M-phase-injected group could also be due to parthenogenetic development. Of 75 M-phase-injected oocytes, 2 were lysed during intracytoplasmic sperm injection and 10 failed to fertilize. The remaining 63 (84%) exhibited normal fertilization morphology with two pronuclei and two polar bodies, inconsistent with parthenogenic activation. Similar results were obtained from non-injected controls and S-phase-injected embryos (extended data table 2 of the original study 3 ). Moreover, SNP analyses provided in Tables 1 and 2 for WT/WT embryos in the M-phase-injected group clearly demonstrate retention of paternal SNPs. To further exclude the possibility of parthenogenetic development, we confirmed the paternal contribution in WT/WT ES cell lines derived from M-phase-injected embryos by short tandem repeat (STR) assay. As expected, all six ES cell lines derived by M-phase injection and one non-injected control (extended data figure 3a of the original study 3 ) contained both maternal and paternal STR alleles (Extended Data Table 5 ). Thus, in all samples we analysed, paternal contribution was detected and parthenogenesis could be ruled out.
Mounting evidence suggests that the two parental homologues provide more than a genetic diversity contributed by parents 8 . Recent developments in custom-designed nucleases allowing selective targeting of one of the two parental alleles have provided evidence for inter-chromosomal pairing, interaction and contribution to DNA repair across plant and animal species. Among the possible interactions are DNA DSB repair governed by mitotic recombination or homologue-template-based repair contributing to LOH 9 . A more recent study using mutant tomato plants with different fruit colours concluded that in heterozygous plants, CRISPR-Cas9-induced DSBs in the targeted allele were repaired using the intact allele as a template at a frequency up to 14% and that HDR between homologues occurred in the absence of the meiotic machinery 10 . Specific targeting of the mutant paternal allele in heterozygous mice also demonstrated that DSB repair, via HDR using the wild-type maternal allele, resulted in the birth of viable WT/WT offspring 11 . DSB induction in both parental alleles simultaneously could also induce template-mediated repair using endogenous genomic sequences from close homologous gene families. In human zygotes, CRISPR-Cas9 based bi-allelic targeting of the β-globin gene (HBB) resulted in HDR using the endogenous δ-globin gene (HBD) 12 .
On the basis of our original results 3 and those present here, we suggest that human embryos have the capacity for non-meiotic homologous chromosome-based DNA repair. This endogenous repair competence must be further explored, reproduced with different founder mutations, and perhaps evaluated for future germline gene therapeutic applications. Many questions remain concerning the precise mechanisms involved during homologous chromosome-based HDR and cell cycle timing. However, given that such DNA repair seems widely conserved across different species, in depth mechanistic studies can potentially be addressed in model organisms. Indeed, a recent article in bioRxiv confirmed our findings in the mouse using more rigorous analyses 13 . Wilde et al. 13 validated high frequency of inter-homologue HDR mechanism in mouse heterozygous zygotes and demonstrated a significant increase of this process by complementing with the HDR-associated strand exchange factor RAD51. In the interim, we hope that the questions raised by Egli et al. 2 and Adikusuma et al. 1 and our new results presented here will contribute to a better understanding of the complex nature of DNA repair and serve as a useful platform for further discussions and studies.
Methods
Regulations for studies involving human research participants. Oregon Health & Science University (OHSU) has established a strong regulatory framework that allowed for approval and continued monitoring of this study protocol. Approval was granted by all relevant regulatory bodies; OHSU Institutional IRB Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design
Sample size
Describe how sample size was determined.
Data exclusions
Describe any data exclusions. No data were excluded
Replication
Describe whether the experimental findings were reliably reproduced.
Human embryo HDR and mosaicism findings were reproduced with multiple oocyte donations from different donors. On-target genotyping by Sanger were validated by STR independently
Randomization
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Blinding
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During all on-target and off-target PCR and Sanger sequencing, the personnel was blinded regarding the sample origin Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
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A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars X All samples presented in this study were from our previous Nature publication and sample size was determined based on specific BCA response.
. .
Sperm containing mutant and WT MYBPC3 was randomly injected into oocytes collected from different donors. CRISPR-Cas9 was randomly injected into zygotes.
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